Transcript
Introducing Secondary Intelligence. The first and only evidence based quantitative technology for managing off target safety issues in pharmaceutical r and d. Safety issues contribute to around twenty five percent of drug product attrition.
When issues occur as a result of secondary pharmacology, you can take action. Choose a more selective compound or adjust the chemistry to avoid it. Most former companies screen Canada compounds against a broad panel of off target receptors and get back a report like this one. But data alone without quantitative real world context isn’t particularly informative.
These are some typical questions that need to be asked and answered.
Secondary intelligence software transforms that data into action.
Secondary Intelligence applies quantitative analysis to develop a risk profile for your compound. Here’s a peek at the evidence underpinning list. For each receptor, we plotted a set of reference drugs. These are drugs that specifically target the receptor for their therapeutic activity.
The software automatically compares your test compound to the reference strengths.
The traffic lights and secondary intelligence aligned to the test compound’s risk level. Here, This test compound has a low probability of interaction with a receptor X. So you can’t proceed without further investigation.
The test compound has a medium risk level at receptor y, suggesting no further investigation unless the predicted Cmax increases.
However, the test compound has a high risk level at receptor z, indicating the need for further investigation or even switching to another compound.
Underlying the software or five elements. First, a list of all drugs targeting the receptor, the main organs or organ system is affected. The commonest associated side effects, the liability of most concern, expected safety pharmacology outcomes, and translatable biomarkers.
Second, constructed mechanistic safety pathways for the most noteworthy side effects associated with the receptor interactions, along with literature citations.
Third, the software delivers a quantitative comparison of where your test compound sits in relation to drugs targeting the receptor for clinical efficacy.
Fourth, multiple ways of visualizing your data, including multi compound comparisons are available.
And finally, a reporting word is generated automatically.
The data underpinning this new where includes an evaluation of over one thousand reference drugs for more than seventy five receptors.
Secondary Intelligence has been recognized by r and d one hundred for its innovation. It is the first and only software tool that quantitatively predicts the risk of safety issues derived from secondary pharmacology, which may impede the clinical development of a drug.
